Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
20
KROS Quote, Financials, Valuation and Earnings
Last price:
$13.74
Seasonality move
:
8.33%
Day range:
$13.42 - $13.77
52-week range:
$9.12 - $72.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.48x
P/B ratio:
0.77x
Volume:
289.3K
Avg. volume:
660.8K
1-year change:
-70.37%
Market cap:
$558.9M
Revenue:
$3.6M
EPS (TTM):
-$0.18
Analysts' Opinion
-
Consensus RatingKeros Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.20, Keros Therapeutics has an estimated upside of 112.21% from its current price of $13.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $13.76.
Fair Value
-
According to the consensus of 11 analysts, Keros Therapeutics has 112.21% upside to fair value with a price target of $29.20 per share.
KROS vs. S&P 500
-
Over the past 5 trading days, Keros Therapeutics has overperformed the S&P 500 by 0.73% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Keros Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Keros Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Keros Therapeutics reported revenues of $211.2M.
Earnings Growth
-
Keros Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Keros Therapeutics reported earnings per share of $3.62.
Enterprise value:
-161.7M
EV / Invested capital:
-0.22x
Price / LTM sales:
2.48x
EV / EBIT:
-12.00x
EV / Revenue:
-0.75x
PEG ratio (5yr expected):
-0.40x
EV / Free cash flow:
-3.73x
Price / Operating cash flow:
12.32x
Enterprise value / EBITDA:
-10.95x
Gross Profit (TTM):
--
Return On Assets:
0.72%
Net Income Margin (TTM):
1.96%
Return On Equity:
0.78%
Return On Invested Capital:
0.78%
Operating Margin:
71.97%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $214.7M | $83K | $211.2M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$122.5M | -$177.2M | -$9.1M | -$48.5M | $152M | |
| EBITDA | -$118.6M | -$161.7M | $14.8M | -$48.2M | $152.4M | |
| Diluted EPS | -$4.40 | -$5.15 | -$0.18 | -$1.21 | $3.62 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $256M | $231.2M | $362.2M | $463.1M | $759.5M | |
| Total Assets | $257.7M | $235.1M | $384.4M | $485.8M | $784.6M | |
| Current Liabilities | $9M | $11.6M | $15.5M | $18.7M | $39.4M | |
| Total Liabilities | $9.4M | $11.6M | $29.5M | $31.9M | $55.7M | |
| Total Equity | $248.4M | $223.5M | $355M | $453.9M | $728.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$102.9M | -$134.8M | $44.9M | -$44.6M | $161.2M | |
| Cash From Investing | -$2.2M | -$2.3M | -$1.6M | -$946K | -$565K | |
| Cash From Financing | $227.9M | $228.1M | $235M | $156.8M | $4K | |
| Free Cash Flow | -$105M | -$137.2M | $43.3M | -$45.5M | $160.6M | |
KROS
Sector
Market Cap
$558.9M
$32.8M
Price % of 52-Week High
19.01%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
-55.35%
-0.74%
1-Year Price Total Return
-70.37%
-35.38%
Beta (5-Year)
1.306
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$13.61
200-day SMA
Sell
Level
$29.23
Bollinger Bands (100)
Buy
Level
10.84 - 14.1
Chaikin Money Flow
Buy
Level
10.9M
20-day SMA
Sell
Level
$14.15
Relative Strength Index (RSI14)
Sell
Level
47.47
ADX Line
Sell
Level
19.92
Williams %R
Neutral
Level
-78.4689
50-day SMA
Sell
Level
$13.99
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
4.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.493)
Buy
CA Score
(Annual)
Level (-0.2606)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.4552)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Stock Forecast FAQ
In the current month, KROS has received 5 Buy ratings 6 Hold ratings, and 0 Sell ratings. The KROS average analyst price target in the past 3 months is $29.20.
-
Where Will Keros Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Keros Therapeutics share price will rise to $29.20 per share over the next 12 months.
-
What Do Analysts Say About Keros Therapeutics?
Analysts are divided on their view about Keros Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Keros Therapeutics is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Keros Therapeutics's Price Target?
The price target for Keros Therapeutics over the next 1-year time period is forecast to be $29.20 according to 11 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is KROS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Keros Therapeutics is a Hold. 6 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of KROS?
You can purchase shares of Keros Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Keros Therapeutics shares.
-
What Is The Keros Therapeutics Share Price Today?
Keros Therapeutics was last trading at $13.74 per share. This represents the most recent stock quote for Keros Therapeutics. Yesterday, Keros Therapeutics closed at $13.76 per share.
-
How To Buy Keros Therapeutics Stock Online?
In order to purchase Keros Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 4.4% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 2.81% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 14.18% over the past day.
